Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.